BREAKING–First-in-Man Oral Proteolytic and Thrombolytic Dissolution of Intra-Arterial COVID-19 Vaccine Thrombi
- Complex Blend of Oral Enzymes and Natural Ingredients Clears Brain Fog and Removes Impending Stroke Risk in Heavily Vaccinated Patient
Feb 24, 2025
By Peter A. McCullough, MD, MPH
*** begin quote ***
While McCullough Protocol Base Spike Protein Detoxification with Ultimate Spike Detox has quickly grown to a global standard for managing long-COVID and complications after COVID-19 vaccination, at the McCullough Foundation we continue to seek innovative solutions to more rapidly and completely manage the health problems brought on by the pandemic.
In this breaking interview, Dr. Takuji Shirasawa from the Ochanomizu Health and Longevity Clinic describes a 60-year old Japanese man who took 4 Pfizer COVID-19 vaccines and presented with a loss of mental clarity otherwise known as “brain fog.” Shirasawa used MR angiography to demonstrate sessile bilateral arterial thrombi in the carotid bulbs. His hypothesis was that mini-blood clots may be responsible for the neurological and cognitive symptoms.
Shirasawa performed a N-of-1 trial giving the patient a complex blend of oral proteolytic and thrombolytic enzymes featuring nattokinase, bromelain, serrapeptase, and papain adding over a dozen natural ingredients given in proprietary blends from Texas based Phytomedic Labs. The patient was also administered aspirin 100 mg per day.
*** end quote ***
This certainly good news. It proves that “brain fog” really does exist by MR angiography. So anyone who says the symptoms are all in your head is correct but not in the way they mean it (i.e., psychosomatic).
I was also fascinated by the term of art “N-of-1 trial” that I never heard of.
https://en.wikipedia.org/wiki/N_of_1_trial
*** begin quote ***
An N of 1 trial (N=1) is a multiple crossover clinical trial, conducted in a single patient.[1] A trial in which random allocation is used to determine the order in which an experimental and a control intervention are given to a single patient is an N of 1 randomized controlled trial. Some N of 1 trials involve randomized assignment and blinding, but the order of experimental and control interventions can also be fixed by the researcher.[2]
This type of study has enabled practitioners to achieve experimental progress without the work of designing a group comparison study. This design, especially if including blinding and wash-out periods, can be effective in confirming causality. N-of-1 trials, if used in clinical practice to inform therapeutic decisions concerned with the patient participating in the trial, can be a source of evidence about individual treatment responses, fulfilling the promise of personalized medicine.[3][4]
*** end quote ***
Never heard that before. Heard of “case reports” as anecdotal evidence. But those were always dismissed as “unscientific”.
As always, this is just hearsay until it happens to you or a loved one.
Nice to know such a treatment exists and appears to work.
—30—
Reinke Faces Life 